1. Home
  2. SMID vs IPHA Comparison

SMID vs IPHA Comparison

Compare SMID & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$27.89

Market Cap

211.2M

Sector

Industrials

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

SELL

Current Price

$1.22

Market Cap

119.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SMID
IPHA
Founded
1960
1999
Country
United States
France
Employees
N/A
174
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
211.2M
119.1M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
SMID
IPHA
Price
$27.89
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
4.5K
11.9K
Earning Date
11-13-2025
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
866.67
N/A
EPS
1.96
N/A
Revenue
$78,508,000.00
N/A
Revenue This Year
N/A
$28.31
Revenue Next Year
N/A
N/A
P/E Ratio
$14.24
N/A
Revenue Growth
31.77
N/A
52 Week Low
$25.16
$1.31
52 Week High
$43.62
$2.63

Technical Indicators

Market Signals
Indicator
SMID
IPHA
Relative Strength Index (RSI) 22.17 21.88
Support Level N/A N/A
Resistance Level $38.16 $1.88
Average True Range (ATR) 1.94 0.08
MACD -1.03 -0.04
Stochastic Oscillator 3.19 2.79

Price Performance

Historical Comparison
SMID
IPHA

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: